Galectin Therapeutics (GALT) News Today $3.19 -0.19 (-5.62%) As of 10/23/2026 04:00 PM Eastern Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Galectin Therapeutics Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above Two Hundred Day Moving Average - What's Next?October 24 at 2:59 AM | marketbeat.comGalectin Therapeutics (NASDAQ:GALT) Stock Price Breaks Above 200 Day Moving Average - Here's WhyOctober 16, 2026 | marketbeat.comGalectin Therapeutics (NASDAQ:GALT) Shares Cross Above Two Hundred Day Moving Average - Here's WhyOctober 8, 2026 | marketbeat.comGalectin: $105M Debt Conversion Clears The Balance Sheet, But Phase 3 Partnership Is CriticalOctober 6, 2026 | seekingalpha.comGalectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026October 6, 2026 | globenewswire.comGalectin Therapeutics (NASDAQ:GALT) Stock Price Crosses Above Two Hundred Day Moving Average - Time to Sell?September 30, 2026 | marketbeat.comGalectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 10, 2026 | globenewswire.comGalectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business UpdateAugust 14, 2026 | globenewswire.comGalectin Therapeutics Announces Conversion of $105.8 Million in Debt to Common Stock by Chairman Richard E. UihleinAugust 4, 2026 | quiverquant.comQGalectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance SheetAugust 4, 2026 | globenewswire.comGalectin Therapeutics Insider Trading Activity | NASDAQ:GALT | BenzingaJuly 14, 2026 | benzinga.comGalectin Therapeutics Corporate Event Calendar | NASDAQ:GALTJuly 12, 2026 | benzinga.comInsider Selling: Galectin Therapeutics (NASDAQ:GALT) Insider Sells 4,570 SharesJuly 1, 2026 | insidertrades.comGalectin Therapeutics (NASDAQ:GALT) Insider Khurram Jamil Sells 7,557 SharesJune 26, 2026 | insidertrades.comGalectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 UpsideJune 24, 2026 | seekingalpha.comGALT stock surges 22% — on track for best day in over a year after FDA clears path for late-stage belapectin trialJune 23, 2026 | msn.comGalectin Therapeutics Reaches FDA Agreement on Phase 3 Endpoint and Regulatory Path for Belapectin Full ApprovalJune 23, 2026 | quiverquant.comQGalectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal HypertensionJune 23, 2026 | globenewswire.comGalectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH CirrhosisMay 27, 2026 | markets.businessinsider.comGalectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH CirrhosisMay 27, 2026 | globenewswire.comAnalysts Are Bullish on Top Healthcare Stocks: Immuneering (IMRX), Galectin Therapeutics (GALT)May 16, 2026 | theglobeandmail.comGalectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business UpdateMay 15, 2026 | globenewswire.comGalectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of HepatologyMay 11, 2026 | globenewswire.comGalectin Therapeutics, Inc. Investigated by the Portnoy Law FirmApril 27, 2026 | globenewswire.comGalectin Therapeutics Reports 2025 Financial Results and Provides Business UpdateMarch 31, 2026 | markets.businessinsider.comGalectin Therapeutics Inc.: Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.March 17, 2026 | finanznachrichten.deGalectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.March 17, 2026 | markets.businessinsider.comGalectin Therapeutics Inc. (GALT) Discusses Updated Results for Belapectin in Treatment of MASH Cirrhosis and Portal Hypertension TranscriptMarch 10, 2026 | seekingalpha.comGalectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and ...February 26, 2026 | markets.businessinsider.comGalectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALTFebruary 22, 2026 | tipranks.comGalectin Therapeutics Halts Key NASH Cirrhosis Trial, Resetting Expectations for GALTFebruary 20, 2026 | tipranks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALTJanuary 22, 2026 | prnewswire.comGalectin Therapeutics Inc.'s (NASDAQ:GALT) top owners are retail investors with 55% stake, while 20% is held by insidersJanuary 22, 2026 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALTJanuary 15, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALTJanuary 13, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALTJanuary 8, 2026 | prnewswire.comGALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with the Schall Law FirmJanuary 7, 2026 | globenewswire.comKhurram Jamil Sells 13,055 Shares of Galectin Therapeutics (NASDAQ:GALT) StockJanuary 7, 2026 | insidertrades.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALTJanuary 6, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALTJanuary 1, 2026 | prnewswire.comGALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law FirmDecember 29, 2025 | businesswire.comGalectin Therapeutics: Runway With Convertible Financing But Dilution Overhang RemainsDecember 24, 2025 | seekingalpha.comGalectin Therapeutics (GALT) price target increased by 83.33% to 11.22December 21, 2025 | msn.comGalectin Therapeutics (NASDAQ:GALT) CEO Joel Lewis Sells 7,829 SharesDecember 20, 2025 | insidertrades.comGalectin Therapeutics stock plummets after FDA feedback on drugDecember 19, 2025 | za.investing.comWhy did GALT shares plummet over 30% today?December 19, 2025 | msn.comInsider Selling: Galectin Therapeutics (NASDAQ:GALT) Major Shareholder Sells 30,681 Shares of StockDecember 19, 2025 | insidertrades.comGalectin Therapeutics Receives FDA Feedback on Belapectin Development Program and Secures $10 Million FinancingDecember 19, 2025 | quiverquant.comQGalectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to ...December 19, 2025 | markets.businessinsider.comHC Wainwright & Co. maintains Galectin Therapeutics (GALT) buy recommendationDecember 18, 2025 | msn.com Galectin Therapeutics Media Mentions By Week Galectin Therapeutics Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GALT News Sentiment▼0.670.46▲Average Healthcare News Sentiment Galectin Therapeutics News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GALT Articles This Week▼12▲GALT Articles Average Week Galectin Therapeutics Trends on MarketBeatThis week vs. last weekNew Followers1-50%Searches1Page Views1,808-5% Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies AVBP News RIGL News KURA News MLTX News CRVS News ALMS News ABUS News VSTM News AKTS News GERN News News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Galectin Therapeutics dated 10/24/2026. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredReport: OCC clears Trump-linked bankLast month I told investors that a Trump-backed crypto bank could be approved any day. On August 14, it was...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
